Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University - 1 Jun 2026

Lin Jialin, Xu Hangcheng, Zhou Yiran, Sa Qiang, Wang Jiayu, Xu Binghe

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) is a promising noninvasive biomarker in advanced breast cancer. In patients with advanced HER2-positive disease, responses to targeted therapy vary. The prognostic significance of ctDNA mutations across different genes and treatment regimens remains to be fully clarified. OBJECTIVES: This meta-analysis evaluated the predictive role of ctDNA mutations in guiding anti-HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Erb-b2 Receptor Tyrosine Kinases

Share to PIK3CA gene

Share to Molecular Targeted Therapy

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 42345502
DOI: 10.17219/acem/209957

Genes

ERBB2
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.PMID 42345502Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.Semantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.Semantic proximity Read ↗

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read ↗

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studySemantic proximity Read ↗

Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.